RegeneRx takes away cash from Lee's Asian thymosin deal but more needed
This article was originally published in Scrip
Executive Summary
The Hong Kong-based firm Lee's Pharmaceutical has acquired rights in China and other selected Asian markets to RegeneRx Biopharmaceuticals' portfolio of thymosin beta-4 (TB-4) therapeutics, throwing a temporary lifeline to the troubled US firm.